title: How many drugs in the maintenance setting for non-small-cell lung cancer? For what benefit?
abstract: Maintenance treatment has been used for several years inside clinical trials. Meta-analyses have been published. A new clinical trial (AVAPERL) has been recently published. Despite significant increase of progression-free survival (PFS), overall survival (OS) has not been changed with these strategies. Before a transfer into clinical practices and guidelines, new data on economic analyses (the cost effectiveness ratio was very high among specific studies) and quality of life are mandatory.
authors.affiliation: Service de Pathologie Respiratoire CHU Dupuytren, Hôpital du Cluzeau, 87042 Limoges cedex, France. alain.vergnenegre@unilim.fr.
authors.forename: Alain
authors.initials: A
authors.lastname: Vergnenègre
keywords: Maintenance; economics; non-small cell lung cancer (NSCLC)